SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2006
ANTARES PHARMA, INC.
(Exact name of registrant specified in its charter)
(State or other jurisdiction
|(Commission File Number)|| |
|707 Eagleview Boulevard, Suite 414 Exton, PA||19341|
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone, including area code: (610) 458-6200
(Former name and former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 2.02 Results of Operations and Financial Condition.
On May 15, 2006, Antares Pharma, Inc. (the Company) issued a press release announcing the Companys financial results for its first fiscal quarter ended March 31, 2006.
A copy of the Companys press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|99.1||||Press Release dated May 15, 2006.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|ANTARES PHARMA, INC.|
|Date: May 19, 2006||By:|| |
/s/ ROBERT F. APPLE
|Name:||Robert F. Apple|
|Title:||Senior Vice President and Chief Financial Officer|
|99.1||Press Release dated May 15, 2006.|